Natural Killer Cell Therapeutics Market: Is 2026 the Year "Off-the-Shelf" Cancer Killers Finally Outperform CAR-T?
As of January 22, 2026, the natural killer cell therapeutics market is identifying as the most disruptive sub-sector of immunotherapy, with its 2026 valuation reaching approximately $571 million to $985 million depending on the inclusion of directed antibodies. The 2026 landscape is defined by a explosive CAGR of 7.2% to 40.2%, as researchers pivot toward NK cells due to their superior safety...
0 Σχόλια
0 Μοιράστηκε
18 Views